The 15q25.1 chromosomal region harbors two genetically independent signals for nicotine dependence and heavy smoking. The first — rs16969968 in CHRNA5 — encodes a receptor that blunts aversive responses to nicotine, lowering the natural ceiling on how much a person smokes. The second, rs578776, tells a different neurobiological story: located in the 3' untranslated region of CHRNA3¹¹ located in the 3' untranslated region of CHRNA3
The 3' UTR is a post-transcriptional regulatory zone that controls mRNA stability, translation efficiency, and tissue-specific expression through microRNA binding sites and RNA-binding protein interactions, this variant appears to reshape how the reward system responds not to nicotine itself, but to everything else — the natural pleasures of daily life.

The two loci are in low linkage disequilibrium (r² ≈ 0.15), meaning they are inherited independently and a person can carry risk variants at one, both, or neither. This matters clinically: someone carrying GG at rs578776 and GG at rs16969968 simultaneously faces compounded biological barriers to cessation — blunted aversion to heavy smoking plus blunted motivation from non-tobacco rewards.

The Mechanism

Unlike the CHRNA5 Asp398Asn missense variant, which demonstrably reduces receptor calcium influx by ~50%, rs578776's mechanism remains under investigation²² rs578776's mechanism remains under investigation
The 3' UTR location suggests post-transcriptional regulation of CHRNA3 expression — potentially through microRNA binding affinity — but no specific miRNA target site disruption has been confirmed for this exact variant. The variant falls in the 3' UTR of CHRNA3, which encodes the alpha-3 nicotinic acetylcholine receptor subunit. The alpha-3 subunit assembles with beta-2, beta-4, and alpha-5 subunits in the medial habenula and interpeduncular nucleus — structures that regulate both aversive responses to nicotine and tonic dopaminergic signaling to the nucleus accumbens.

The functional readout most convincingly linked to rs578776 is the intrinsic reward sensitivity (IRS) endophenotype³³ intrinsic reward sensitivity (IRS) endophenotype
Measured using the late positive potential (LPP) event-related potential component, which indexes the brain's motivational attention to emotionally significant stimuli at 400–700 ms post-stimulus onset. Smokers who are homozygous for the G allele (plus-strand; C on the coding strand) are dramatically more likely to show the IRS− profile: blunted late positive potential responses to pleasant pictures (food, nature, social scenes) combined with heightened neural reactivity to cigarette-related images. The working model is that sustained nicotinic signaling through CHRNA3-containing receptors gradually recalibrates the dopamine system, narrowing incentive salience toward drug cues and away from natural rewards.

The Evidence

Bierut et al. 2008⁴⁴ Bierut et al. 2008
A family-based GWAS of habitual smoking (≥20 cigarettes/day for ≥6 months) versus light smoking (≤10 cigarettes/day) using the FBAT method identified rs578776 as a second independent locus within the 15q25.1 cluster (p=0.009). The key finding was that rs578776 and rs16969968 have r² < 0.15, establishing statistical independence. The Tobacco and Genetics Consortium subsequently confirmed genome-wide significant association with cigarettes per day⁵⁵ genome-wide significant association with cigarettes per day
The TAG consortium meta-analysis pooled data across multiple European cohorts to reach the p < 5×10⁻⁸ threshold for genome-wide significance.

The most mechanistically informative study was published in Frontiers in Psychiatry in 2013. Versace et al. measured the intrinsic reward sensitivity endophenotype⁶⁶ Versace et al. measured the intrinsic reward sensitivity endophenotype
IRS was classified using LPP amplitude to pleasant pictures vs. cigarette pictures in 104 European-ancestry smokers enrolled in a smoking cessation trial in 104 European-ancestry smokers. The rs578776 G allele (coding-strand C) conferred dramatically higher odds of IRS− membership: carriers of two protective A alleles had an odds ratio of 0.17 (95% CI: 0.07–0.46, p=0.0002) for belonging to the IRS− group — equivalent to approximately 83% lower odds of the reward deficit phenotype.

Critically, the IRS− phenotype itself predicted cessation failure across multiple timepoints: OR=2.73 at 10 weeks, OR=3.06 at 3 months, and OR=4.03 at 6 months post-quit. The SNP genotype alone did not directly predict abstinence (sample too small for individual-SNP power), but through the IRS− intermediate phenotype it indexes a biology that substantially undermines cessation. Notably, standard questionnaire measures — nicotine dependence scales, depression inventories, trait affect — were not associated with rs578776 genotype, suggesting this ERP-based endophenotype captures something qualitatively different from self-reported craving or mood.

Practical Implications

The GG genotype does not cause nicotine dependence in isolation — it describes a particular neurobiological terrain that makes dependence harder to treat once it develops. For never-smokers, awareness of elevated dependence susceptibility is the primary value. For current smokers, understanding the IRS− phenotype reframes cessation strategy: the challenge is not just managing withdrawal but restoring motivation from non-tobacco sources that the dependent brain has learned to undervalue.

Standard cessation aids address nicotine receptor activity and withdrawal; fewer directly target the reward system's blunted response to natural stimuli. Behavioral activation — systematically scheduling engagement with non-drug rewarding activities — is the cessation component most directly matched to the IRS− phenotype. This approach, embedded in cognitive-behavioral therapy for mood disorders, has been adapted for smoking cessation in programs like BSCT (Behavioral Smoking Cessation Treatment) specifically for smokers with anhedonic features.

Varenicline is notable in this context because it acts as a partial agonist at alpha-4/beta-2 receptors, reducing the contrast between smoking and not smoking by maintaining baseline nicotinic tone during cessation — potentially bridging the reward gap while natural reward sensitivity recovers.

Interactions

rs578776 (CHRNA3 3' UTR, Locus 2) is in low LD with all three other 15q25.1 variants already in the GeneOps database: rs1051730 (CHRNA3 Tyr215Tyr, r²≈0.15), rs16969968 (CHRNA5 Asp398Asn, r²<0.15), and rs2036527 (CHRNA5 enhancer, partial LD). A person inheriting risk alleles at rs578776 and rs16969968 simultaneously faces compounded barriers: reduced nicotinic aversion to heavy smoking (CHRNA5 mechanism) and blunted natural reward sensitivity (CHRNA3 Locus 2 mechanism).

Population frequencies at rs578776 differ substantially from the other 15q25.1 variants. In East Asians, the G risk allele is rare (18% frequency) while the protective A allele dominates (82%), a near-inversion of the European pattern (G=72%). This population divergence supports the hypothesis that rs578776 tags a functional variant under distinct evolutionary pressure in different ancestries, separate from the evolutionary forces shaping rs16969968.

Von Willebrand factor (VWF) is a large multimeric glycoprotein that performs two essential roles in hemostasis: it anchors platelets to sites of vascular injury, and it acts as a carrier protein that protects coagulation factor VIII (FVIII) from premature degradation in the bloodstream. When a vessel is damaged, VWF unfolds under shear stress, recruits platelets, and delivers FVIII to the clot site for amplification of the coagulation cascade. VWF is synthesized in endothelial cells and megakaryocytes, stored in Weibel-Palade bodies, and released on demand¹¹ VWF is synthesized in endothelial cells and megakaryocytes, stored in Weibel-Palade bodies, and released on demand
VWF biology overview. The rs61754002 variant creates a premature stop codon that eliminates VWF protein from the affected allele entirely — a so-called null allele with no residual function.

The Mechanism

The VWF gene spans chromosome 12p13.31 on the minus strand, encoding a 2813-amino-acid preproprotein across 52 exons. The rs61754002 variant (c.1071C>A on the coding strand; G>T on the genomic plus strand at position 6,072,369 in GRCh38) lies in exon 9, converting codon 357 from tyrosine (TAC) to a stop codon (TAA) — p.Tyr357Ter, also written Y357X. This is a nonsense mutation²² nonsense mutation
a single nucleotide change that creates a premature stop codon, terminating translation early. The truncated transcript is degraded by nonsense-mediated mRNA decay, producing no detectable VWF protein from the affected allele. In heterozygous carriers, VWF plasma levels are driven entirely by the one functional allele; in homozygous or compound heterozygous individuals, VWF is absent or severely reduced.

The Evidence

The original documentation of this variant comes from a French family study that identified a 20-year-old woman with severe VWD initially misclassified as haemophilia A because her two male first cousins had factor VIII gene mutations³³ two male first cousins had factor VIII gene mutations
a separate F8 gene mutation in the same family created diagnostic confusion. She was found to carry compound heterozygosity: one allele with Y357X (creating no VWF protein) and a second allele with C1060R (a missense mutation in the D3 domain that eliminates FVIII binding). The combined effect was very low VWF antigen, undetectable VWF:FVIII binding, and severely reduced FVIII activity — a phenotype resembling haemophilia A but arising from VWF dysfunction, classified as VWD type 2N.

Hilbert et al. (2003)⁴⁴ Hilbert et al. (2003)
Hilbert L et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of VWF. Br J Haematol. 2003 further characterized the C1060R allele in seven French families with type 2N disease, establishing that D3 domain mutations dramatically reduce VWF:FVIII binding even when located outside the classically defined FVIII-binding tryptic fragment.

Heterozygous carriers of VWF null alleles display a wide range of phenotypes. Pérez-Rodríguez et al. (2006)⁵⁵ Pérez-Rodríguez et al. (2006)
Pérez-Rodríguez A et al. Characterization of recessive severe type 1 and type 3 VWD vs asymptomatic heterozygous carriers. J Thromb Haemost. 2006 found that among obligate carriers of type 3 VWD null alleles, 48% were diagnosed with type 1 VWD and had clinically meaningful bleeding, while the remainder were asymptomatic despite carrying 50% of normal VWF levels. This incomplete penetrance is why carrier testing and standardized bleeding assessment are recommended for any first-degree relative of a type 3 VWD patient.

Practical Actions

For carriers of a single Y357X allele: VWF antigen levels are typically 40–60% of normal, placing many individuals in the "low VWF" or type 1 VWD range. A standardized bleeding assessment — using the ISTH Bleeding Assessment Tool⁶⁶ ISTH Bleeding Assessment Tool
the ISTH-BAT questionnaire scores bleeding history from 12 sites; a score ≥3 in women or ≥2 in men is abnormal — quantifies symptom burden and guides decisions about prophylaxis or treatment around procedures. Desmopressin (DDAVP) can transiently double or triple VWF levels by releasing stored VWF from endothelial Weibel-Palade bodies; response testing should be performed under specialist supervision, as some null-allele carriers respond adequately.

For compound heterozygous or homozygous individuals: VWF replacement using plasma-derived VWF/FVIII concentrates (Alphanate, Humate-P, Wilate) or recombinant VWF (Vonvendi) is the cornerstone of management. Desmopressin is ineffective when both alleles are null. Hematology co-management is required for surgical procedures, trauma, and pregnancy.

Interactions

The Y357X null allele can combine with any second pathogenic VWF variant to produce compound heterozygous disease. When the second allele carries a FVIII-binding domain mutation (such as rs61748497, encoding C1060R — a D3 domain missense that abolishes FVIII binding), the phenotype resembles haemophilia A, and patients are at risk for misdiagnosis. Full VWF gene sequencing should be offered to anyone with confirmed low VWF levels, to identify both alleles and classify the disease subtype accurately.

Blood group O independently lowers VWF antigen levels by 15–25% compared to non-O groups. Carriers of Y357X who also have blood group O may have VWF levels that fall below the type 1 VWD diagnostic threshold (30 IU/dL) even on the heterozygous null-allele background alone.

TMEM18 (Transmembrane Protein 18) sits at the second strongest obesity locus ever discovered by genome-wide association studies, trailing only FTO. The variant rs6548238 lies 23 kilobases upstream of TMEM18 on chromosome 2p25.3, in a regulatory region that influences how much TMEM18 protein the brain produces. What makes this gene remarkable is where it acts: deep within the hypothalamus¹¹ hypothalamus
The brain region that controls hunger, thirst, body temperature, and energy balance, specifically the paraventricular nucleus (PVN)²² paraventricular nucleus (PVN)
A cluster of neurons in the hypothalamus that integrates hunger and satiety signals and regulates energy expenditure, the brain's central command for appetite and energy expenditure.

The Mechanism

TMEM18 encodes a protein with four transmembrane domains that localizes to the nuclear membrane, where it physically interacts with components of the nuclear pore complex³³ nuclear pore complex
The channel through which molecules pass between the cell nucleus and cytoplasm. Its expression in the PVN is nutritionally regulated -- it responds to feeding state and leptin⁴⁴ leptin
The "satiety hormone" produced by fat cells that signals the brain to reduce appetite signaling. In functional studies, mice lacking TMEM18⁵⁵ mice lacking TMEM18
Larder et al. TMEM18 has a role in the central control of appetite and body weight regulation. PNAS, 2017 showed increased body weight driven by hyperphagia (overeating), particularly on a high-fat diet. Conversely, overexpressing TMEM18 in the PVN reduced food intake, increased energy expenditure, and decreased both total body mass and fat mass. This demonstrates that TMEM18 acts as a brake on appetite: less TMEM18 means more eating.

The Evidence

The GIANT consortium GWAS⁶⁶ GIANT consortium GWAS
Willer et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009 first identified this locus in a meta-analysis of over 32,000 individuals, with replication in 59,000 more, reaching genome-wide significance (p = 3.2 x 10^-26) with a per-allele BMI increase of 0.26 kg/m² for the C allele.

A comprehensive meta-analysis⁷⁷ comprehensive meta-analysis
Li et al. The association between polymorphisms near TMEM18 and the risk of obesity: a meta-analysis. BMC Medical Genomics, 2021 pooling 27 studies with 53,395 obesity cases and 123,972 controls confirmed the association with an overall odds ratio of 1.25 (95% CI: 1.08-1.45). The effect was strongest in Europeans (OR 1.32) and Mexicans (OR 1.39). Notably, the association was more robust in children (OR 1.28, 95% CI: 1.18-1.39) than in adults, and one study found TMEM18 variants conferred the strongest effect on pediatric BMI⁸⁸ strongest effect on pediatric BMI
Almen et al. TMEM18 variants associated with BMI and waist circumference in children. European Journal of Human Genetics, 2012 out of 25 obesity-associated variants tested in 6,078 children.

The C allele is very common -- around 83-91% frequency depending on ancestry -- meaning most people carry the risk version. The protective T allele is found in only about 9-17% of chromosomes. Because the risk allele is the major allele, the CC genotype (highest risk) is also the most common genotype (~70% of people).

Practical Implications

Because the C risk allele is so prevalent, carrying CC does not mean inevitable obesity -- it means your hypothalamic appetite signaling provides less restraint than the uncommon TT genotype. The effect is modest per allele (0.26 kg/m² BMI), but it compounds across the many obesity-risk loci each person carries. For CC homozygotes, proactive appetite management strategies -- particularly protein-first meals and structured eating patterns -- can counteract the reduced hypothalamic brake on hunger.

Interactions

TMEM18 acts independently of FTO (rs9939609) and MC4R (rs17782313) -- the three loci are in linkage equilibrium and their effects on BMI are additive. A person carrying risk alleles at all three loci faces a meaningfully higher cumulative genetic load for obesity than someone with risk alleles at only one. While no synergistic gene-gene interaction has been documented (each adds its own effect independently), the combined burden of risk alleles across FTO, TMEM18, and MC4R creates a significantly higher baseline appetite drive that warrants proactive management strategies.

Every gram of dietary leucine — the most anabolic amino acid, abundant in meat, dairy, and protein powders — is funnelled through a five-step mitochondrial enzymatic cascade before it can be burned for energy or converted to acetyl-CoA. The third and rate-limiting step belongs to isovaleryl-CoA dehydrogenase (IVD)¹¹ isovaleryl-CoA dehydrogenase (IVD)
A mitochondrial flavoenzyme that converts isovaleryl-CoA to 3-methylcrotonyl-CoA, consuming one molecule of FAD per reaction; named for the sweaty-feet odor of isovaleric acid that accumulates when IVD fails. When IVD runs efficiently, leucine flows cleanly through to energy. When it stalls, the metabolic intermediate isovalerylcarnitine (C5-carnitine)²² isovalerylcarnitine (C5-carnitine)
A blood and urine metabolite that directly reflects IVD enzyme activity; the primary neonatal screening marker for isovaleric acidemia; measured as part of acylcarnitine panels rises.

rs66791338 is not a coding variant — it sits within an intron of IVD, 5 base pairs of sequence (AAAGG) either present or absent. Yet this tiny structural difference is the primary functional variant at the IVD locus³³ primary functional variant at the IVD locus
Confirmed by Brown et al. 2024 (PMID 37930192) using luciferase reporter assays and CRISPR/Cas9 homology-directed repair in lymphoblastoid cell lines, directly controlling how much IVD protein the cell produces. The deletion allele (−AAAGG) is the derived form that arose more recently in human evolutionary history — and it is better. It increases IVD expression, accelerates leucine catabolism, and is under positive selection in Japanese populations, where it reaches ~80% frequency compared to ~22% in Africans.

The Mechanism

The five base pairs at rs66791338 fall within an intronic enhancer⁴⁴ intronic enhancer
A non-coding DNA element that binds transcription factors and boosts nearby gene transcription; enhancers can act across thousands of base pairs from the promoter that regulates IVD transcription. The insertion allele (I) disrupts enhancer geometry or transcription factor binding, reducing IVD mRNA output. The deletion allele (D) restores or optimizes the enhancer, driving higher IVD expression.

IVD itself is a flavoprotein⁵⁵ flavoprotein
An enzyme that requires FAD (flavin adenine dinucleotide), derived from riboflavin (vitamin B2), as a tightly bound cofactor for catalytic activity. In riboflavin-deficient mitochondria, IVD activity can fall to 17% of control levels⁶⁶ 17% of control levels
Measured in rat liver mitochondria; the mature enzyme degrades rapidly without FAD stabilization, independent of gene expression level. This creates a compounding vulnerability: if the I allele already reduces IVD expression, and riboflavin intake is marginal, enzyme activity can fall through two independent mechanisms simultaneously.

Brown et al. 2024 showed the deletion allele associates with a 0.088 unit decrease in isovalerylcarnitine⁷⁷ 0.088 unit decrease in isovalerylcarnitine
Normalized to propionylcarnitine in 4,678 TwinsUK participants; r²=0.40, P<2×10⁻¹⁶ for the correlation between variant-expression associations and variant- metabolite associations. Lower isovalerylcarnitine reflects more efficient substrate processing — the metabolic equivalent of a clean-running combustion cycle.

The Evidence

The functional case for rs66791338 as the causal regulatory variant rests on two pillars. First, luciferase reporter assays⁸⁸ luciferase reporter assays
Placing the variant sequence upstream of a reporter gene and measuring light output as a proxy for transcriptional activity; the gold standard for testing regulatory variant function directly demonstrated that the deletion allele drives higher enhancer activity. Second, CRISPR/Cas9 homology-directed repair experiments — converting endogenous insertions to deletions and vice versa in cell lines — confirmed that the indel causally changes IVD mRNA levels, not merely correlates with them. This bidirectional experimental confirmation is rare for regulatory variants in complex disease genetics.

The population genomics case is equally striking. The JPT (Japanese from Tokyo) population⁹⁹ JPT (Japanese from Tokyo) population
One of the East Asian populations in the 1000 Genomes Project; used as a reference for East Asian ancestry in population genetics shows a positive selection peak centered on the IVD locus, suggesting the high-expression deletion haplotype conferred a fitness advantage in ancestral East Asian environments. The deletion allele reaches ~80% in East Asians versus ~22% in Africans — a striking disparity that is unlikely to reflect genetic drift alone at a locus of this size.

The connection to idiopathic pulmonary fibrosis (IPF)¹⁰¹⁰ idiopathic pulmonary fibrosis (IPF)
A progressive, irreversible lung scarring disease affecting ~3 in 10,000 people; median survival 3-5 years after diagnosis; etiology involves fibrogenic signaling in alveolar epithelium comes from GWAS evidence: Fingerlin et al. 2013¹¹¹¹ Fingerlin et al. 2013
1,616 non-Hispanic white IPF cases and 4,683 controls plus replication cohort identified the 15q14-15 region containing IVD as a genome-wide significant IPF locus. The causal link between IVD expression and pulmonary fibrosis is likely mediated through isovaleryl-CoA accumulation driving mitochondrial dysfunction and fibrogenic signaling in alveolar epithelial cells — plausible but not directly demonstrated.

Practical Actions

For II carriers (insertion homozygous) — the ancestral, lower-expression genotype common in Africans (~78%) — two nutritional considerations are directly supported by the biochemistry. First, riboflavin adequacy is critical: IVD is exquisitely FAD-dependent, and since I-allele carriers already have lower IVD expression, maintaining maximal enzyme activity from available protein through riboflavin sufficiency is especially important. Second, avoiding pharmacological BCAA supplementation limits the isovaleryl-CoA substrate burden on a system running at reduced capacity.

For DI carriers — heterozygotes — the evidence is consistent with an intermediate phenotype. The same riboflavin consideration applies but with less urgency.

DD carriers have the highest IVD expression and most efficient leucine catabolism. No specific interventions are indicated beyond maintaining the riboflavin intake that enables IVD to function at its genetically determined maximum.

This variant does not relate to classical isovaleric acidemia (IVA), which is caused by biallelic pathogenic coding variants in IVD that abolish enzyme function entirely. The I allele of rs66791338 is a common regulatory variant affecting expression quantitatively, not a disease-causing mutation.

Interactions

rs66791338 is the primary functional variant within a three-variant regulatory haplotype at the IVD locus, co-inherited with rs10851395 and rs111540938. The high-expression haplotype carries the deletion at rs66791338 together with the ancestral alleles at the other two SNPs, producing a synergistic boost in IVD transcription. The nearby intronic variant rs2034650 is a widely studied tag variant in linkage disequilibrium with this haplotype, explaining why rs2034650 shows the IPF and isovalerylcarnitine associations despite not being directly functional.

No published gene-gene interactions between rs66791338 and variants in downstream leucine catabolism enzymes (3-methylcrotonyl-CoA carboxylase, electron transfer flavoprotein) have been identified, though such interactions are biologically plausible.

The interleukin-23 receptor (IL-23R) sits at the center of the IL-23/Th17 axis¹¹ IL-23/Th17 axis
A cytokine signaling pathway linking innate immune sensing to adaptive T-helper 17 cell responses; the primary target of anti-IL-23 biologics including risankizumab, guselkumab, and ustekinumab used in IBD, psoriasis, and ankylosing spondylitis, one of the most therapeutically targeted pathways in modern inflammatory disease. When IL-23 binds its receptor on CD4+ T cells, innate lymphoid cells, and natural killer cells, it drives differentiation and survival of Th17 cells that produce IL-17A — the cytokine responsible for the neutrophil-dominated tissue inflammation seen in psoriasis, ankylosing spondylitis, psoriatic arthritis, and Crohn's disease. rs6693831 is an intronic variant within the IL23R gene on chromosome 1, where the minor T allele (~21.8% globally) is associated with increased susceptibility to ankylosing spondylitis, while the common C allele confers a substantial protective effect.

The Mechanism

rs6693831 lies within an intron of IL23R (NM_144701.3:c.1149-653T>C, GRCh38 position chr1:67255184) on the plus strand of the gene. As an intronic variant, it does not directly alter the IL-23R protein sequence. However, intronic variants in this gene frequently act as linkage disequilibrium tags²² linkage disequilibrium tags
Intronic SNPs that co-segregate with nearby functional variants on the same chromosomal haplotype, so that the intronic SNP captures the disease association even when it is not itself the causal variant for regulatory elements or coding variants on the same IL23R haplotype block. The IL23R locus contains multiple independent association signals organized into haplotype blocks; rs6693831 tags a signal distinct from the well-characterized rs11209026 (R381Q, Arg381Gln) missense variant, which is the primary IL23R protective allele studied across European populations.

Whether rs6693831 acts through direct regulation of IL23R expression levels or through LD with a nearby functional element has not been resolved experimentally. Given the large allele frequency differences across ancestries — the T allele is notably rarer in African (~7.6%) compared to European (~26.4%) and American (~37.7%) populations — the clinical signal is most robustly established in East Asian cohorts where the majority of studies have been conducted.

The Evidence

The most statistically compelling data for rs6693831 comes from a case-control study in Southwest China³³ case-control study in Southwest China
Yang et al. Oncotarget 2017, PMID 29050281 — 486 ankylosing spondylitis patients and 480 healthy controls genotyped using high-resolution melting analysis, which found the C allele strongly protective against AS (p=3.206×10⁻³¹) and the CC genotype independently associated with reduced AS susceptibility (p=8.574×10⁻⁸). These extremely significant p-values place rs6693831 among the most robustly associated IL23R variants tested in this Chinese cohort for AS.

In the direction of risk for rheumatoid arthritis, a 2024 case-control study in Western China⁴⁴ 2024 case-control study in Western China
Ren et al. Int J Immunogenet 2024, PMID 38196067 — 246 RA patients and 362 controls found the C allele and CC genotype were more frequent in RA patients than in controls (OR=7.797 for CC vs TT, OR=5.984 for allele C vs T). This finding runs in the opposite direction from the AS study, suggesting rs6693831 may have disease-specific bidirectional effects — a pattern documented at the IL2RA locus and other immune-regulatory genes where the same pathway component plays opposing roles in different autoimmune disease contexts. The RA study's small sample (n=608) and unusually large odds ratios for a common intronic variant warrant replication before firm RA-specific guidance can be offered.

A third study examining alcohol-induced osteonecrosis of the femoral head⁵⁵ alcohol-induced osteonecrosis of the femoral head
Wang et al. Oncotarget 2017, PMID 28422712 — 355 male cases and 355 controls in a Chinese Han population found the TC heterozygous genotype to function as a protective factor (p=0.046), consistent with a broadly modulatory role for this variant in inflammatory susceptibility.

The evidence base for rs6693831 is currently anchored in Chinese Han populations from three small-to-moderate case-control studies. The extraordinary significance of the AS association (p~10⁻³¹) suggests a real biological effect in that population, but independent replication in European and other ancestries is lacking. The evidence level is accordingly rated moderate.

Practical Implications

For carriers of two T alleles (TT genotype, ~4.8% of people globally), the AS association data from Chinese cohorts suggests meaningfully elevated susceptibility to ankylosing spondylitis — an axial spondyloarthropathy characterized by chronic back pain, progressive spinal fusion, and systemic inflammation. Early recognition of AS symptoms enables timely rheumatology referral and initiation of disease-modifying therapy that can prevent irreversible structural damage. The IL-23/Th17 axis is directly targeted by approved biologics for AS (secukinumab, ixekizumab for IL-17A; ustekinumab, risankizumab for IL-23), making pathway-level genetic risk genuinely informative for treatment planning.

The contradictory RA signal from the smaller Ren 2024 study means the TT genotype should not be considered protective against RA on current evidence. The most defensible interpretation is: TT = elevated AS risk (robust finding), uncertain RA implications (requires replication).

For CT heterozygotes (~34.1% of people), one copy of the T allele confers intermediate risk for AS under an additive model, with less data available to quantify the effect precisely.

Interactions

rs6693831 is one of six IL23R variants in this research batch, tagging an independent haplotype signal distinct from the canonical rs11209026 R381Q missense protective allele and from other intronic IL23R markers (rs7517847, rs10489629, rs2201841, rs1004819). Multiple IL23R variants can be present simultaneously on different haplotypes; their combined effect has not been formally modeled in the studies available for rs6693831. Given the IL23R gene's complex haplotype structure with at least three independent disease-association blocks documented in European and Asian populations, individuals carrying risk alleles at multiple IL23R SNPs may have compounded susceptibility beyond what any single variant predicts.

The IL-23/Th17 pathway interacts functionally with HLA-B*27 in ankylosing spondylitis (HLA-B*27 is the dominant AS genetic risk factor, present in ~90% of AS patients) — the combined effect of HLA-B*27 and IL23R risk alleles has not been quantified for rs6693831 specifically. A compound action describing IL23R × HLA-B*27 interaction should be considered if data emerge for this specific SNP.

The ESR1 gene encodes estrogen receptor alpha (ERα)¹¹ estrogen receptor alpha (ERα)
the primary nuclear receptor through which estradiol controls gene transcription in reproductive tissues; ERα-driven signaling is essential for endometrial proliferation and implantation, and its dysregulation is central to endometriosis pathogenesis, the most pharmacologically targeted protein in endometriosis management. Endometriosis affects roughly 1 in 10 women of reproductive age — causing pelvic pain, dysmenorrhea, dyspareunia, and infertility — and estrogen is essential for the growth and persistence of ectopic lesions. Variants that shift ERα expression or activity are therefore credible contributors to disease susceptibility.

rs73625113 sits in an intronic region of ESR1 at chromosome 6q25.1 and was identified as a high-confidence causal variant at this locus through Bayesian fine-mapping, with a posterior inclusion probability (π) of 0.506 — meaning the statistical evidence assigns approximately a 50% probability that this specific variant, rather than a neighboring tag SNP, is the functional change driving the association signal. It is one of only a small number of variants genome-wide that reached this level of fine-mapping resolution in endometriosis genetics.

The Mechanism

The T allele at rs73625113 does not alter the ESR1 protein sequence — it lies in a non-coding intronic region. Its biological effect operates through gene regulation. Fine-mapping analyses show that rs73625113 is in strong linkage disequilibrium (r² > 0.8) with rs2941739²² rs2941739
a nearby variant identified as an expression quantitative trait locus (eQTL) for ESR1 in blood tissue; eQTLs are variants that alter the amount of mRNA produced from a gene, and with multiple methylation quantitative trait loci (mQTLs) at CpG sites near ESR1. Together, this evidence points to rs73625113 marking a regulatory region that influences ESR1 transcription and local chromatin methylation.

ESR1 expression in endometrial tissue governs the proliferative response to estradiol across the menstrual cycle. When ERα signaling is constitutively elevated or dysregulated — as altered ESR1 eQTLs would predict — endometrial stromal cells become hypersensitive to estrogen, potentially facilitating ectopic implantation and lesion maintenance. ESR1 also regulates expression of COMT (catechol-O-methyltransferase), a key enzyme in the catabolism of pain-relevant catecholamine neurotransmitters including dopamine and epinephrine; this secondary pathway may explain why the 6q25.1 locus is particularly enriched for pain subphenotypes beyond what pure lesion burden would predict.

The Evidence

The 6q25.1 ESR1 locus was first established as genome-wide significant for endometriosis in the Sapkota et al. 2017 GWAS meta-analysis³³ Sapkota et al. 2017 GWAS meta-analysis
17,045 cases and 191,596 controls; 5 novel loci identified: FN1, CCDC170/ESR1, SYNE1, FSHB; together explaining up to 5.19% of disease variance. The locus houses multiple genes — CCDC170, ESR1, and SYNE1 — and the 2017 analysis could not distinguish which was the primary causal gene.

The Rahmioglu et al. 2023 mega-GWAS⁴⁴ Rahmioglu et al. 2023 mega-GWAS
60,674 cases and 701,926 controls of predominantly European ancestry; 42 genome-wide significant loci comprising 49 distinct signals; fine-mapping using Bayesian credible sets; significant genetic correlations with 11 pain conditions including migraine and multisite chronic pain resolved this ambiguity. Through Bayesian fine-mapping, rs73625113 (intronic to ESR1) emerged with π=0.506 as a high-confidence causal candidate distinct from the neighboring SYNE1 variant rs71575922 (π=0.997). This indicates the 6q25.1 locus harbors at least two independent functional variants — one in SYNE1 and one in ESR1 — each contributing to the overall association signal through different biological mechanisms.

The pain subphenotype analyses in the 2023 study revealed striking effect size enrichment: while the 6q25.1 locus overall shows a modest OR for endometriosis diagnosis, the pain-specific signals are substantially larger — dysmenorrhea OR 1.49, dyspareunia OR 1.48, severe dyspareunia OR 2.07, and acyclical pelvic pain OR 1.44. This pattern supports a model in which the ESR1 regulatory variant contributes to pain amplification — partly through direct estrogenic effects on nociceptive pathways, and partly through the downstream COMT pathway governing catecholamine catabolism.

Practical Actions

Carrying the T allele at rs73625113 is most clinically meaningful as a pain-risk signal in endometriosis. Women with endometriosis who carry T may be predisposed to more severe dysmenorrhea and dyspareunia than the lesion burden alone would predict, because the ESR1/COMT regulatory pathway shapes how the nervous system processes pelvic nociception. Monitoring pain subphenotypes separately from lesion staging and discussing estrogen-modulating interventions with a gynecologist familiar with this mechanism are the most actionable responses to this result.

For those who have not yet received an endometriosis diagnosis: a T-allele result in this gene does not diagnose the condition, but it supports a lower threshold for seeking specialist evaluation of pelvic pain symptoms rather than normalizing dysmenorrhea. The average diagnostic delay for endometriosis remains 4–11 years from symptom onset.

Interactions

rs71575922 (SYNE1, 6q25.1): This SNP is co-located at the same GWAS locus but represents a distinct fine-mapped signal (π=0.997 for SYNE1 vs. π=0.506 for ESR1 at rs73625113). Women carrying risk alleles at both variants carry the full genetic burden of the 6q25.1 locus — both the neuromechemical (SYNE1/Nesprin-1) and estrogen receptor (ESR1) pathways converge on pain amplification at this locus.

Supervisor compound action proposal: women carrying both the rs71575922 G allele (SYNE1) and the rs73625113 T allele (ESR1) represent the highest genetic burden at the 6q25.1 locus, with two independently fine-mapped signals both enriched for pain subphenotypes. Proposed combined recommendation: integrated pain management addressing both neuromuscular dysfunction (pelvic floor PT, neuromodulation) and estrogen-signaling contributions (tracking cycle-linked vs. cycle-independent pain, discussion with specialist about estrogen-lowering hormonal options). Evidence level: moderate (both loci independently established; combined effect inferred from locus biology, not directly studied).

rs12700667 (HOXA cluster, 7p15.2): A second major endometriosis GWAS locus; the HOXA cluster regulates endometrial receptivity and Müllerian development, suggesting a complementary mechanism (lesion biology/stromal invasion) that may act additively with the ESR1 pain-pathway signal at this locus.

Interleukin-17F (IL-17F)¹¹ Interleukin-17F (IL-17F)
a Th17 effector cytokine closely related to IL-17A that shares receptor components IL-17RA and IL-17RC and drives overlapping but distinct inflammatory programs is one of the signature outputs of Th17 cells — the immune subset central to defense against extracellular bacteria and fungi and, when dysregulated, to the tissue damage seen in autoimmune conditions like psoriasis, ankylosing spondylitis, and inflammatory bowel disease. While IL-17A (encoded nearby on chromosome 6p12) has received more attention, IL-17F is produced at higher levels by Th17 cells and contributes substantially to neutrophil recruitment, epithelial antimicrobial peptide production, and mucosal barrier defense.

The rs763780 variant introduces a single amino acid change — histidine to arginine at position 161 (His161Arg) — in a protein only 163 residues long after signal peptide cleavage. That position sits at the very C-terminus of the mature protein within the cystine-knot fold that both IL-17A and IL-17F share. The result is a natural variant that functions as a dominant-negative antagonist of its own wild-type counterpart.

The Mechanism

IL-17F signals through a heteromeric receptor complex of IL-17RA and IL-17RC²² IL-17RA and IL-17RC
IL-17RA is ubiquitously expressed; IL-17RC provides ligand-binding specificity. Both are required for downstream signaling, which proceeds through the adaptor Act1 to NF-κB and MAPK pathways. In bronchial epithelial cells, wild-type IL-17F activates MAPK signaling cascades and induces production of IL-8, IL-6, and other pro-inflammatory mediators that recruit neutrophils and amplify mucosal inflammation.

The His161Arg variant (H161R) fails to activate the MAPK pathway and cannot induce cytokine or chemokine production in bronchial epithelial cells³³ His161Arg variant (H161R) fails to activate the MAPK pathway and cannot induce cytokine or chemokine production in bronchial epithelial cells
Functional assays in Kawaguchi et al. 2006 showed H161R protein had no measurable MAPK activation or IL-8 induction, unlike wild-type IL-17F at equivalent concentrations. More strikingly, the variant protein actively blocked wild-type IL-17F signaling, demonstrating dominant-negative behavior: heterozygous carriers produce both wild-type and H161R protein, and the H161R form competes with wild-type at the receptor level, reducing net IL-17F signaling below even that of non-carriers.

The histidine at position 161 lies in the mature protein's C-terminal region within the cystine-knot fold critical for homodimerization and receptor engagement. The arginine substitution likely disrupts dimer interface geometry or receptor contact residues, producing a protein that can occupy receptor-proximal space without transducing signal — the structural basis for its antagonist activity.

The Evidence

The landmark study by Kawaguchi et al.⁴⁴ landmark study by Kawaguchi et al.
Journal of Allergy and Clinical Immunology, 2006; n=867 Japanese subjects demonstrated that CC homozygosity was inversely associated with asthma risk with an odds ratio of 0.06 (95% CI 0.01–0.43; p=0.0039) — a striking 94% reduction in asthma odds for carriers of two His161Arg alleles, remaining significant after adjustment for atopy (p=0.0079). This was one of the first demonstrations of a naturally occurring dominant-negative cytokine variant with direct impact on inflammatory disease.

The protective signal extends to other Th17-driven conditions. In Takayasu arteritis — a large-vessel vasculitis with prominent Th17 involvement⁵⁵ Takayasu arteritis — a large-vessel vasculitis with prominent Th17 involvement
Danda et al. 2017; combined analysis across two replication phases, n=218 cases, 220 controls, the C allele was significantly protective (OR 0.44, 95% CI 0.25–0.77; p=0.0029). In ulcerative colitis, the wild-type T allele (His161) confers increased risk⁶⁶ ulcerative colitis, the wild-type T allele (His161) confers increased risk
Arisawa et al. 2008, with the T allele identified as an independent risk factor, particularly for the chronic continuous phenotype and pancolitis.

A meta-analysis of IL-17F rs763780 across 14 studies and 8,124 gastric cancer cases⁷⁷ meta-analysis of IL-17F rs763780 across 14 studies and 8,124 gastric cancer cases
Elshazli et al. 2018 found no significant association with gastric cancer risk, suggesting the variant's protective effects are not universal across all inflammatory disease contexts.

The trade-off becomes apparent in infectious disease data. In a Chinese Han tuberculosis study⁸⁸ Chinese Han tuberculosis study
Peng et al. 2013; 596 PTB + 176 EPTB cases, 622 controls, the C allele was enriched in tuberculosis cases, suggesting that reduced IL-17F activity — while dampening autoimmune inflammation — impairs protective Th17 responses against intracellular pathogens. Similarly, bladder cancer studies found the T allele (functional IL-17F) associated with greater antitumor immune surveillance effects.

The ClinVar classification as "benign" for familial candidiasis 6 reflects that the His161Arg variant alone does not cause the severe mucocutaneous candidiasis phenotype linked to complete IL-17F loss-of-function; the Ser95Leu variant in the same gene is responsible for that rare disease. However, reduced IL-17F activity from His161Arg may contribute to increased susceptibility to mucosal Candida colonization at a subclinical level.

Practical Actions

For TC heterozygotes, the dominant-negative activity of the Arg161 protein partially dampens IL-17F signaling from the wild-type allele. This is broadly beneficial for reducing autoimmune inflammatory burden, but carriers should maintain vigilance for mucosal infections — oral thrush, recurrent vaginal yeast infections, nail fungal infections — as these may signal reduced IL-17F-dependent mucosal defense.

For CC homozygotes, the strong protective effect against autoimmune disease means this variant is more likely to be clinically relevant as a protective marker than a risk factor. However, the near-complete loss of IL-17F activity warrants proactive monitoring for signs of impaired mucosal immunity: persistent Candida infections, recurrent sinopulmonary bacterial infections, and delayed wound healing at mucosal surfaces all warrant prompt evaluation.

If anti-IL-17 biologics (secukinumab, ixekizumab, bimekizumab) are considered for any Th17-driven condition, TC or CC genotype status provides biological context: these individuals already have naturally reduced IL-17F activity, so IL-17 inhibition adds to that baseline reduction; monitoring for fungal infections during biologic therapy is especially warranted.

Interactions

The rs763780 His161Arg variant operates in direct functional opposition to the IL-17A rs2275913 promoter variant⁹⁹ IL-17A rs2275913 promoter variant
the -197G>A variant increases NFAT binding affinity and amplifies IL-17A transcription, elevating Th17-driven inflammation. Individuals carrying the IL-17A risk allele (rs2275913 A) together with functional IL-17F (rs763780 TT) have the highest net Th17 cytokine output; those carrying both the IL-17A promoter risk allele and the IL-17F His161Arg variant exist in a partially offset state, where elevated IL-17A is partially counterbalanced by reduced IL-17F.

Upstream, IL-23R rs2201841¹⁰¹⁰ IL-23R rs2201841
intronic variant that increases IL-23 pathway activity and expands Th17 cells influences how many Th17 cells produce both IL-17A and IL-17F. Carrying the IL-23R risk allele alongside rs763780 CC produces an unusual combination: expanded Th17 pools making high IL-17A but with most IL-17F output neutralized by the dominant-negative variant.

SMAD3 is the central intracellular messenger of TGF-beta (transforming growth factor-beta) signaling¹¹ TGF-beta (transforming growth factor-beta) signaling
TGF-beta is a cytokine that controls immune cell differentiation and tolerance; when TGF-beta binds its receptor, SMAD2/3 are phosphorylated and translocate to the nucleus to regulate gene transcription, the master pathway governing immune tolerance and the differentiation of regulatory T cells (Tregs). In the immune system, Tregs depend on TGF-beta–SMAD3 signaling both to develop and to suppress inflammatory responses — keeping the immune system from attacking self-tissues and preventing runaway allergic reactions. The rs17293632 T allele is an intronic regulatory variant that alters SMAD3 expression through an allele-specific enhancer, tilting the balance of TGF-beta signaling in immune cells with consequences that extend across the allergy-autoimmunity spectrum.

The Mechanism

rs17293632 sits within an intron of the SMAD3 gene at chromosome 15q22.33 (position 67,150,258 on GRCh38). Functional luciferase assays²² Functional luciferase assays
Reporter assays in which the variant sequence drives expression of a luminescent protein, allowing direct measurement of allele-specific transcriptional activity confirmed that this variant and the nearby rs4562997 act as allele-specific enhancer elements — meaning the two alleles differ in their capacity to drive SMAD3 transcription. This was further validated in vascular smooth muscle cells using CRISPRi and lentiMPRA³³ vascular smooth muscle cells using CRISPRi and lentiMPRA
CRISPRi silences endogenous enhancers; lentiMPRA screens thousands of sequences simultaneously for enhancer activity, yielding a mechanistic fingerprint, confirming that rs17293632 is a true functional eQTL with measurable allele-specific enhancer activity — not merely a tag for a nearby functional variant.

The consequence of altered SMAD3 expression in T cells is a disruption of the homeostatic balance between Tregs, Th2 cells (allergic immune responses), and Th17 cells (autoimmune/mucosal inflammation). SMAD3 is required for Foxp3 induction (the master transcription factor of Tregs) and simultaneously restrains Th2 differentiation. When SMAD3 activity is dysregulated, immune tolerance falters in both directions: insufficient Treg suppression of Th2 responses drives allergic sensitization, while insufficient Treg control of mucosal immunity impairs the gut's ability to tolerate commensal bacteria — the basis for Crohn's disease susceptibility.

The Evidence

The Ferreira et al. 2017 Nature Genetics meta-analysis of 360,838 participants across multiple cohorts⁴⁴ 360,838 participants across multiple cohorts demonstrated that the SMAD3 locus is one of 136 genome-wide significant risk loci for allergic disease, with the same allele conferring risk across asthma, hay fever, and eczema — implying a shared biological mechanism rather than disease-specific effects. The study found that shared risk variants predominantly influence lymphocyte-mediated immunity, with SMAD3 fitting squarely in this pattern as a central regulator of T cell differentiation. Notably, only 6 of the 136 loci showed disease-specific effects, making SMAD3 a pan-allergic rather than asthma-specific or eczema-specific risk gene.

On the autoimmune side, Franke et al. 2010 in Nature Genetics⁵⁵ Franke et al. 2010 in Nature Genetics implicated SMAD3 among 71 confirmed Crohn's disease susceptibility loci in a meta-analysis of six GWAS datasets (6,333 cases, 15,056 controls in the discovery phase, followed up in 29,720 additional individuals). This dual signal — same locus appearing in both allergic and Crohn's disease GWAS — is the hallmark of the immune tolerance axis: when TGF-beta–SMAD3 signaling is suboptimal, the immune system loses discriminatory restraint in both directions.

Clinically, SMAD3 rs17293632 predicts disease course in established Crohn's disease. O'Donnell et al. 2019⁶⁶ O'Donnell et al. 2019 in a North American cohort of IBD patients found that rs17293632 was among eight susceptibility variants associated with accelerated time-to-abdominal surgery (P < 0.05), suggesting the variant influences not just disease onset but disease severity and progression. The Brylak et al. 2025 pediatric IBD study⁷⁷ Brylak et al. 2025 pediatric IBD study of 286 Polish children observed that specific rs17293632 genotypes were associated with increased systemic corticosteroid requirements in Crohn's disease — a proxy for more refractory, steroid-dependent disease.

Practical Implications

The T allele at rs17293632 signals impaired TGF-beta tolerance capacity. This does not guarantee disease — penetrance is low and most T allele carriers remain disease-free — but it places the immune system closer to the threshold for both allergic sensitization and mucosal inflammation. The gut microbiome is a key environmental modifier: diverse, fiber-fermenting bacteria generate short-chain fatty acids (SCFAs) and produce signals that amplify TGF-beta–SMAD3 signaling⁸⁸ amplify TGF-beta–SMAD3 signaling
SCFAs, particularly butyrate, promote Foxp3+ Treg differentiation partly through SMAD3-dependent mechanisms, potentially compensating for reduced baseline SMAD3 activity in T allele carriers.

High-fiber, plant-diverse dietary patterns consistently associate with greater microbiome diversity and enhanced Treg populations in the gut mucosa, providing a tractable, genotype-informed dietary target for this variant. Monitoring for early signs of both allergic disease and inflammatory bowel disease is warranted for those carrying two T alleles.

Interactions

SMAD3 operates in a pathway network with IL13 (rs20541), which encodes the Th2 cytokine that counterbalances TGF-beta signaling, and with IL10 (rs1800795), a key anti-inflammatory cytokine that works alongside TGF-beta to suppress mucosal inflammation. Carriers of T alleles at rs17293632 who also carry risk alleles at IL13 or reduced IL10 production variants face compounding impairment of immune tolerance capacity. Within the SMAD3 gene, rs4562997 is a second functional enhancer variant that interacts with rs17293632 in allele-specific transcriptional regulation — carriers of risk haplotypes across both positions may have more substantially altered SMAD3 expression than rs17293632 alone would predict.

The RNF213 gene encodes a massive 591-kilodalton protein that sits at the intersection of vascular biology and immune function. Best known as the primary genetic determinant of moyamoya disease¹¹ moyamoya disease
a progressive cerebrovascular disorder characterised by stenosis of the terminal internal carotid arteries and compensatory collateral vessel formation, resembling a "puff of smoke" on angiography, RNF213 variants have now been linked to the much more common condition of migraine — pointing to shared neurovascular mechanisms across a spectrum of cerebrovascular pathology.

The Met270Thr change sits in the N-terminal region of RNF213, distant from the C-terminal AAA+ ATPase domain where the high-penetrance East Asian founder mutation p.R4810K resides. Unlike R4810K — which carries an extraordinary odds ratio of ~190 for moyamoya disease in Japanese cohorts — Met270Thr carries a modest effect on migraine risk (OR=1.06) and is classified as benign in ClinVar for moyamoya disease itself. Yet its genome-wide significant association with migraine in one of the largest headache genetics studies ever conducted suggests it tags something real about vascular regulation and headache susceptibility.

The Mechanism

RNF213 acts as an unconventional E3 ubiquitin ligase with intrinsic ATPase activity. It participates in multiple converging roles: regulating angiogenesis and vascular remodeling, controlling lipid metabolism, modulating cerebral blood flow, and responding to inflammatory and hypoxic stimuli. In endothelial cells, the protein is required for normal arterial wall formation — loss-of-function models show impaired vascular remodeling under stress conditions (carotid ligation), with defective adaptive responses that mirror, in attenuated form, the negative remodeling pattern seen in moyamoya arteries.

The Met270Thr substitution replaces a methionine with a more hydrophilic threonine at position 270 of the protein. This N-terminal region is less functionally characterized than the disease-critical C-terminal ATPase domain, but the missense change likely modulates the protein's ubiquitin ligase activity or protein-protein interaction surfaces. RNF213's established role in the Hippo pathway²² Hippo pathway
a conserved signalling cascade regulating cell growth, apoptosis, and vascular morphogenesis; loss of RNF213 activates the YAP/TAZ effectors, driving pathological endothelial proliferation provides a plausible molecular link between impaired RNF213 function and the neurovascular dysfunction that underlies migraine.

Migraine pathophysiology itself implicates vascular and central nervous system tissue types — a finding confirmed by enrichment analyses in the large-scale migraine GWAS. RNF213's role in regulating intracranial arterial calibre and the response of vessel walls to haemodynamic stress positions the Met270Thr variant as a plausible contributor to the cerebrovascular component of migraine susceptibility.

The Evidence

The primary evidence for rs17857135 in migraine comes from the Gormley et al. 2016 meta-analysis³³ the Gormley et al. 2016 meta-analysis
Gormley P et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature Genetics, 2016, which analysed 59,674 migraine cases and 316,078 controls across 22 studies. The C allele at rs17857135 reached p=5×10⁻¹⁰ with an odds ratio of 1.06 and a risk allele frequency of 0.17 — placing it firmly in the genome-wide significant tier alongside 37 other loci mapping to vascular and central nervous system pathways.

An independent replication signal at the RNF213 locus emerged from the Hsu et al. 2023 genome-phenome-wide association study⁴⁴ the Hsu et al. 2023 genome-phenome-wide association study
Hsu WT et al. Genome-phenome wide association study of broadly defined headache. Brain Communications, 2023 in 108,855 Han Chinese participants from the Taiwan Biobank (12,026 headache cases). The lead variant at the RNF213 locus, rs8072917, reached OR=1.08, p=4.49×10⁻⁸; fine-mapping confirmed this as the most likely causal variant in this population, with the RNF213 gene region representing one of the strongest associations for broadly defined headache in Han Chinese.

The broader context for RNF213 in cerebrovascular disease is well-established. The gene was first identified as the moyamoya disease locus through twin GWAS in 2011: Kamada et al.⁵⁵ Kamada et al.
Kamada F et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet, 2011 and Liu et al.⁶⁶ Liu et al.
Liu W et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One, 2011, collectively demonstrating that RNF213 loss-of-function impairs the arterial remodeling that sustains cerebrovascular perfusion.

Practical Actions

The OR of 1.06 for migraine associated with rs17857135-C is clinically modest at the individual level — about a 6% relative increase in migraine odds per allele. However, the mechanism it implicates is actionable: RNF213 variants affect intracranial vascular tone and endothelial function, suggesting that interventions targeting vascular health are particularly relevant for C-allele carriers with migraine. These include cerebrovascular monitoring if migraine attacks change in character or frequency, and awareness that migraine with aura specifically is a recognised independent stroke risk factor.

For CC homozygotes (the top-risk genotype at this locus), the cerebrovascular connection warrants closer clinical attention: any new focal neurological symptoms accompanying headache should prompt early neuroimaging to exclude transient ischaemic attack or moyamoya-pattern vascular changes, even though this variant is itself benign for frank moyamoya disease.

Interactions

RNF213 Met270Thr is distinct from the high-penetrance moyamoya variants in RNF213 (particularly p.R4810K, which is absent from this SNP). However, the same gene's vascular biology creates a plausible pathway interaction with other migraine-associated loci involved in neurovascular function, including CACNA1A (calcium channel) variants that affect trigeminovascular signalling. The RNF213 locus signal for headache appears independent in both European and Han Chinese populations, suggesting it is not merely a proxy for other vascular variants.

Carriers of rs17857135-C who also have migraine with aura carry a compounded cerebrovascular risk profile: aura itself is associated with increased stroke risk, and the RNF213 vascular remodeling pathway adds a second, mechanistically distinct vulnerability. This interaction is worth discussing with a neurologist if both are present.

The A1298C variant (rs1801131) is the second most-studied MTHFR variant. While C677T gets most of the attention, A1298C also affects MTHFR enzyme activity, though through a different mechanism and with a milder effect.

The Mechanism

The A1298C variant causes a glutamic acid-to-alanine substitution ¹¹ Glutamic acid-to-alanine substitution at position 429 of the protein (p.Glu429Ala) at position 429 of the MTHFR protein. This position is in the regulatory domain of the enzyme (whereas C677T affects the catalytic domain), which is why its effect on enzyme activity is milder. The GG genotype ²² CC on the coding strand — 23andMe reports the complementary strand reduces MTHFR activity by about 30-40%, compared to the 70% reduction seen with C677T TT. ClinVar classifies this variant as benign on its own, as neither homozygotes nor heterozygotes show significantly elevated homocysteine in most studies.

Compound Heterozygosity

The most clinically relevant scenario involving A1298C is compound heterozygosity ³³ Compound heterozygosity: carrying one variant copy at each of two different positions in the same gene — carrying one variant at C677T (AG) AND one variant at A1298C (GT). This combination can reduce MTHFR activity to a degree similar to being homozygous for C677T alone (about 40-50% reduction). If you carry variants at both positions, you should pay closer attention to your folate and methylation status.

The Evidence

Studies show that A1298C alone has a weaker association with elevated homocysteine⁴⁴ weaker association with elevated homocysteine
Population studies show A1298C alone has minimal effect on homocysteine levels compared to C677T. However, compound heterozygotes⁵⁵ compound heterozygotes
Weisberg I et al. Compound heterozygosity of C677T and A1298C reduces MTHFR activity, 2001 (one copy of each) show homocysteine levels intermediate between normal and C677T homozygous individuals. This matters because many people who are "only heterozygous" for C677T may actually have meaningful methylation impairment if they also carry an A1298C variant.

Practical Considerations

If you are GG at A1298C, treat your methylation support similarly to having moderate C677T impairment. If you are compound heterozygous (AG at C677T + GT at A1298C), consider the same approach as for C677T TT: methylfolate supplementation, adequate B12 and B2, and periodic homocysteine monitoring.

Interactions

The A1298C variant interacts with C677T (rs1801133) in compound heterozygosity. It also interacts with SLC19A1 (rs1051266) for overall folate pathway efficiency and with MTHFD1 (rs2236225) for one-carbon metabolism capacity.